Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
122.92
-3.48 (-2.75%)
At close: Mar 28, 2025, 4:00 PM
125.00
+2.08 (1.69%)
After-hours: Mar 28, 2025, 5:42 PM EDT
Jazz Pharmaceuticals Revenue
In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth. Jazz Pharmaceuticals had revenue of $1.09B in the quarter ending December 31, 2024, with 7.53% growth.
Revenue (ttm)
$4.07B
Revenue Growth
+6.12%
P/S Ratio
1.87
Revenue / Employee
$1,453,196
Employees
2,800
Market Cap
11.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
JAZZ News
- 3 days ago - Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 10 days ago - Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting - PRNewsWire
- 19 days ago - CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX - Business Wire
- 24 days ago - Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
- 24 days ago - Jazz Pharmaceuticals to buy Chimerix for $935 million - Reuters
- 24 days ago - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio - GlobeNewsWire
- 4 weeks ago - Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab - Seeking Alpha
- 4 weeks ago - Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript - Seeking Alpha